Kiniksa Pharmaceuticals, Ltd. provided earnings guidance for the full-year 2022. For the year, the company expects ARCALYST net revenue for the full-year 2022 to be between $115 million and $130 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.77 USD | +0.05% | -1.52% | +7.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.01% | 1.33B | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Earnings Guidance for the Full-Year 2022